PROCEPT BioRobotics Corporation · Healthcare · Medical Devices
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$17.58
−$0.57 (−3.13%) 3:59 PM ET
After hours$17.59
+$0.01 (+0.05%) 3:36 AM ET
Prev closePrevC$18.15
OpenOpen$18.57
Day highHigh$18.68
Day lowLow$17.54
VolumeVol820,509
Avg volAvgVol1,397,992
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.04B
EV/Sales
2.56
P/E ratio
-9.16
FY Revenue
$337.34M
EPS
-1.92
Gross Margin
64.22%
Div yield
0.00%
Sector
Healthcare
AI report sections
MIXED
PRCT
PROCEPT BioRobotics Corporation
PRCT shows short-term price momentum with the latest close above key moving averages and positive 1M and 3M returns, yet longer-term performance remains weak with the stock down sharply over 6 and 12 months and trading near the lower half of its 52-week range. Fundamentally, the company combines solid gross margins and modest revenue growth with persistent operating losses, negative free cash flow, and declining operating cash generation. Valuation multiples appear elevated relative to current profitability and cash flow metrics, while heightened short interest and negative legal-focused news flow highlight sentiment and headline risk.
NegativeGlobeNewswire Inc.• Shareholders Foundation, Inc.
LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation
A lawsuit was filed on July 24, 2026, against PROCEPT BioRobotics Corporation alleging the company misrepresented U.S. handpiece unit sales through an undisclosed discount program that incentivized bulk orders beyond actual demand, artificially inflating reported sales and exposing the company to material operational and financial risks.
PRCTCRWVsecurities violationmisrepresentationdiscount programhandpiece unit salesoverstockingclass action lawsuit
Sentiment note
The company faces a securities class action lawsuit alleging material misrepresentation of sales figures through undisclosed discount practices, artificial inflation of reported metrics, and concealment of operational risks. These allegations directly harm investor confidence and indicate potential financial and legal consequences.
NegativeGlobeNewswire Inc.• Grabar Law Office
Important Notice to Long-Term Shareholders of Doximity, Inc. (NYSE: DOCS); GoDaddy Inc. (NYSE: GDDY); Planet Fitness, Inc. (NYSE: PLNT); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office announced investigations into potential breaches of fiduciary duties by officers and directors at Doximity, GoDaddy, Planet Fitness, and PROCEPT BioRobotics. The investigations follow federal securities class action filings alleging misleading statements regarding business metrics, pricing strategies, and financial guidance. Long-term shareholders meeting specific holding periods are eligible to seek corporate reforms and potential compensation at no cost.
Company allegedly used undisclosed discount programs to artificially inflate handpiece sales, created excess field inventory exceeding 10,000 units, and issued unachievable 2025 guidance.
Deadline Alert: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, leading to excess inventory of over 10,000 units. Stock price declined significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.
The company is accused of securities fraud involving material misstatements about business operations and financial condition. Undisclosed discount programs artificially inflated sales figures, leading to excess inventory accumulation. Stock declined 13.35%, 9.74%, and 15.12% on three separate negative announcements, resulting in significant investor losses.
NegativeGlobeNewswire Inc.• Kaplan Fox & Kilsheimer Llp
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026
Kaplan Fox has filed a class action lawsuit against PROCEPT BioRobotics Corporation for allegedly misleading investors about the relationship between handpiece unit sales and procedures. The complaint alleges that undisclosed discount programs artificially inflated reported U.S. handpiece unit sales and revenues by pulling forward demand. Investors who purchased PROCEPT common stock between February 28, 2024 and February 25, 2026 may be eligible to participate in the class action, with a deadline of September 22, 2026 to seek a lead plaintiff role.
The company is the subject of a securities class action lawsuit alleging fraudulent misrepresentation regarding sales practices and revenue reporting. The allegations of undisclosed discount programs artificially inflating sales figures and misleading investor communications represent serious legal and reputational risks.
INVESTOR DEADLINE: PROCEPT BioRobotics Corporation (PRCT) Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit Before September 22, 2026
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly misleading investors about handpiece sales through undisclosed bulk discount programs that artificially inflated revenues. The company pulled forward sales from future quarters to meet expectations, resulting in excess customer inventory of over 10,000 units. PROCEPT shares declined over 48% from August 2025 to February 2026 as the truth emerged through a series of earnings misses and subsequent disclosures.
The company is accused of deliberately misleading investors about handpiece sales through undisclosed bulk discount programs designed to artificially inflate revenues and pull forward sales. Multiple earnings misses, a 48% stock price decline, and the elimination of the discount program indicate serious operational and governance issues that resulted in substantial investor losses.
NegativeGlobeNewswire Inc.• Rosen Law Firm
PROCEPT DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action – PRCT
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding handpiece unit sales and revenues. The lawsuit claims the company used undisclosed discount programs to artificially inflate sales figures, created excess inventory of over 10,000 units, and failed to disclose material risks. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation, with a September 22, 2026 deadline to serve as lead plaintiff.
PRCTsecurities class actionPROCEPT BioRoboticsfalse statementsdiscount programinventory overstockinginvestor compensationlead plaintiff deadline
Sentiment note
The company is the subject of a securities class action lawsuit alleging materially false and misleading statements about sales figures, undisclosed discount programs that artificially inflated revenues, excess inventory of over 10,000 units, and inability to achieve stated guidance. These allegations indicate significant operational and financial misconduct.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, A LONGSTANDING FIRM, Encourages Doximity, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – DOCS
Rosen Law Firm has filed class action lawsuits against Doximity, Inc., PROCEPT BioRobotics Corporation, and DNOW Inc. on behalf of investors who suffered losses. The Doximity lawsuit alleges the company overstated its Newsfeed's revenue impact and lost market share to competitors. Investors with losses exceeding $100,000 are encouraged to seek counsel before upcoming deadlines.
Company is subject to a securities class action lawsuit with an upcoming September 22 deadline, indicating investor claims of misconduct or material misstatements.
NegativeGlobeNewswire Inc.• Rosen Law Firm
DNOW DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages DNOW Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – DNOW
Rosen Law Firm reminds investors in DNOW Inc., PROCEPT BioRobotics Corporation, and Doximity Inc. of upcoming deadlines to join securities class action lawsuits. DNOW faces allegations of false statements regarding merger challenges with MRC Global, while similar class actions have been filed against the other companies. Investors must act by specified deadlines to potentially recover damages.
DNOWPRCTDOCSsecurities class actionlead plaintiff deadlineDNOW Inc.PROCEPT BioRoboticsDoximity Inc.
Sentiment note
Company is subject to a securities class action lawsuit with an upcoming September 22 deadline, indicating alleged investor harm and legal disputes.
NegativeGlobeNewswire Inc.• Rosen Law Firm
WIX.COM DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Wix.com Ltd. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action – WIX
Rosen Law Firm has filed securities class action lawsuits against Wix.com Ltd., PROCEPT BioRobotics Corporation, and Doximity, Inc. The lawsuits allege that defendants made false and misleading statements regarding product performance, costs, and financial benefits. Investors who purchased securities during specified class periods are encouraged to secure counsel before the September 22, 2026 deadline to potentially join the litigation.
WIXPRCTDOCSsecurities class actionfalse statementsinvestor compensationlead plaintiff deadlineAI product offerings
Sentiment note
Company is defendant in securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations and investor losses.
Bragar Eagel & Squire, P.C Urges PROCEPT BioRobotics Corporation Investors to Contact the Firm Seeking Lead Plaintiff Role Before September 22nd
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding its handpiece unit sales and revenues. The company allegedly used an undisclosed extensive discount program to artificially inflate sales by pulling forward orders, creating over 10,000 excess units in field inventory and causing the company to miss its 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 can apply to be lead plaintiff by September 22, 2026.
The company is accused of making materially false and misleading statements about sales and revenues through an undisclosed discount program that artificially inflated numbers, created excessive inventory, and resulted in failure to meet stated guidance. These allegations indicate serious accounting and disclosure violations with significant investor harm.
NegativeGlobeNewswire Inc.• Schall, Brown & Schwartz Llp
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for violations of the Securities Exchange Act. The lawsuit alleges the company made false and misleading statements by using large discounts to inflate current revenue, pulling orders forward, and materially overstating handpiece unit utilization. The class period spans February 28, 2024 to February 25, 2026, with a September 22, 2026 deadline for investors to participate.
The company is accused of making false and misleading statements to the market, artificially inflating revenue through aggressive discounting practices, and overstating asset utilization. These allegations of securities fraud and investor losses warrant a negative sentiment rating.
PRCT 6-DAY DEADLINE ALERT: PROCEPT BioRobotics Corporation Investors Alerted to September 22, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
A securities class action has been filed against PROCEPT BioRobotics for allegedly misleading investors about handpiece sales performance. The company allegedly used undisclosed bulk order discount programs to artificially inflate sales figures by pulling forward future quarter sales, resulting in excess customer inventory exceeding 10,000 units. The stock declined over 48% from August 2025 to February 2026 as the truth emerged through quarterly earnings misses and management disclosures.
The company is accused of deliberately misleading investors about sales performance through undisclosed discount programs designed to artificially inflate quarterly results. Multiple earnings misses, a 48% stock price decline, and revelations of excess customer inventory (10,000+ units) indicate serious operational and transparency issues that resulted in substantial investor losses.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal